Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11522537 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL25816376 | 0.79 | CHRNB2 (0.32) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL29048263 | 0.79 | CHRNB2 (0.32) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL22232773 | 0.79 | SLC18A3 (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18921517 | 0.79 | SLC18A3 (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1638748 | 0.79 | SLC18A3 (0.39) | MEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29048286 | 0.78 | CHRNB2 (0.32) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL29048250 | 0.78 | CHRNB2 (0.32) | CHRNB2CHRNA4 | |
| SCHEMBL30678228 | 0.78 | CYP11B1 (0.38) | CHRNB2CHRNA4CYP2A6CYP1A2CYP11B2 | |
| SCHEMBL22444813 | 0.74 | TNKS (0.34) | CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | VORONOI INC. (KR) | 2025-01-16 | — | — | US | disclosed |
| EP-4421077-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | Voronoi Inc. (KR) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023068881-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | 주식회사 보로노이바이오 | 2023-04-27 | — | — | WO | disclosed |
| US-20220242870-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | VORONOIBIO INC. (KR) | 2022-08-04 | — | — | US | disclosed |
| WO-2022131741-A1 | ISOXAZOLIDINE DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2022-06-23 | — | — | WO | disclosed |
| WO-2022131741-A1 | ISOXAZOLIDINE DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2022-06-23 | — | — | WO | disclosed |
| EP-3971190-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Voronoi Inc. (KR) | 2022-03-23 | — | — | EP | disclosed |
| WO-2020235902-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | 주식회사 보로노이 (KR) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242870-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | CDK4, CDK6, CDK16 | CHRNB2 4798/4885CHRNA4 4561/4885CHRNA7 4389/4885 |
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | RIPK1, RIPK2, RIPK3 | CHRNB2 4278/4885CHRNA4 4640/4885CHRNA7 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.